0
Articles |

A Comparison of Double-Strength Beclomethasone Dipropionate (84 µg) MDI With Beclomethasone Dipropionate (42 µg) MDI in the Treatment of Asthma

Robert A. Nathan; Keith B. Nolop; Francis M. Cuss; Richard R. Lorber
Author and Funding Information

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia


1997 by the American College of Chest Physicians


Chest. 1997;112(1):34-39. doi:10.1378/chest.112.1.34
Text Size: A A A
Published online

Abstract

Study objective: To compare the efficacy and safety of a double-strength formulation of beclomethasone dipropionate (BDP 84) metered-dose inhaler (MDI) with that of beclomethasone dipropionate (BDP 42) MDI in the treatment of chronic asthma.

Design: A 28-day, randomized, double-blind, double-dummy, placebo-controlled, multicenter study.

Setting: Outpatient.

Patients: A total of 423 patients aged 12 to 65 years (mean range, 34 to 36 years) with moderate asthma (FEV1, 50 to 80% of predicted) who required long-term inhaled corticosteroids were enrolled.

Interventions: Patients were randomized to receive BDP 84, two oral inhalations bid (336 µg/d), BDP 42, four oral inhalations bid (336 µg/d), or placebo. A fourth treatment arm administering BDP 84, eight oral inhalations bid (HD BDP 84; 1,344 µg/d) was also included to determine whether a dose-response relationship could be demonstrated.

Measurements: Spirometry, clinical observations.

Results: The three active treatments were significantly more effective (p≤0.01) than placebo at all time points in improving FEV1, the primary efficacy parameter; BDP 42 and BDP 84 were comparable to each other at every time point. Secondary pulmonary function tests (FVC, forced expiratory flow at 25 to 75% of FVC, and peak expiratory flow rate) showed similar results. All three active treatments were well tolerated. A dose response between 336 µg/d and 1,344 µg/d was demonstrated.

Conclusion: In this well-controlled 28-day study, BDP 42 and BDP 84 were shown to be comparable in efficacy and safety on a microgram-for-microgram basis.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Inhaled corticosteroids: Effects on growth and bone health. Ann Allergy Asthma Immunol 2016;117(6):595-600.
Safety of intranasal corticosteroids. Ann Allergy Asthma Immunol 2016;117(6):601-605.
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543